AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05478928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Dry needling
Description: An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point for 120 seconds.
Study NCT05478928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed dose static MEP
Description: Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
Study NCT05478928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algorithm-based dose static MEP
Description: Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically, at 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed. Treatment will finish when the patient does not refer any discomfort for a period longer than 60 seconds. Total dose in mC will be registered.
Study NCT05384678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine (108 mg) + dose titration
Description: A dose rate of 1.2 mg/min will be administered with subsequent patient-guided dose titration
Study NCT05478928 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly up to 3 mm deep into the upper trapezius trigger point for 120 seconds.
Study NCT04743817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OtoSet - Ear Cleaning System
Description: Up to five (5) cleaning cycles using the OtoSet - Ear Cleaning System
Study NCT06073886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active cTBS
Description: 600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
Study NCT06073886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active cTBS
Description: 600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
Study NCT06073886 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive/Sham cTBS
Description: 600 inactive, or sham, cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
Study NCT06073886 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imaginal exposure
Description: Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities
Study NCT06073886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Description: Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities
Study NCT06073886 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Imaginal exposure
Description: Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities
Study NCT05353361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811：Pyrotinib
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral
Study NCT05353361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；Pertuzumab
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip
Study NCT05353361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；Adebrelimab
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip
Study NCT05353361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811；Albumin paclitaxel
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip
Study NCT04736394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-1202
Description: APL-1202 single-agent oral treatment
Study NCT04736394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin Hydrochloride
Description: Epirubicin hydrochloride
Study NCT05188196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar ridge preservation
Description: Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.
Study NCT05188196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar ridge preservation
Description: Alveolar ridge preservation and augmentation commonly are performed immediately after tooth extraction to preserve or increase ridge volume within or beyond the skeletal envelope that exists at the time of extraction.
Study NCT04882280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light
Description: 10 hours of light exposure during the daytime, starting 2 hours after habitual wake time
Study NCT05042791 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: radiation combined with pyrotinib and capecitabine
Description: This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases
Study NCT05042791 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: radiation combined with pyrotinib and capecitabine
Description: This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases
Study NCT05886751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Doctor Screening Video
Description: Participants will view an online video with a Black doctor speaking about prostate cancer screening.
Study NCT05886751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Doctor Screening Video
Description: Participants will view an online video with a White doctor speaking about prostate cancer screening.
Study NCT05886751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Patient Screening Video
Description: Participants will view an online video with a Black patient speaking about prostate cancer screening.
Study NCT05886751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Patient Screening Video
Description: Participants will view an online video with a White patient speaking about prostate cancer screening.
Study NCT05886751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Doctor Clinical Trials Video
Description: Participants will view an online video with a Black doctor speaking about prostate cancer clinical trials.
Study NCT05886751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Doctor Clinical Trials Video
Description: Participants will view an online video with a White doctor speaking about prostate cancer clinical trials.
Study NCT05886751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Patient Clinical Trials Video
Description: Participants will view an online video with a Black patient speaking about prostate cancer clinical trials.
Study NCT05886751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Patient Clinical Trials Video
Description: Participants will view an online video with a White patient speaking about prostate cancer clinical trials.
Study NCT05591079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159 (Linafexor)
Description: Oral QD
Study NCT05591079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CS0159 (Linafexor)
Description: Oral QD
Study NCT05718297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib is administered for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent, whatever occurs first. After the treatment period of 3 years, patient's ongoing treatment will be managed according to local standard and best clinical practice.~Brigatinib should be taken approximately at the same time each day. It may be taken with or without food. Patients shall be instructed to swallow the tablets whole and not crush or chew them.
Study NCT05718297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
Study NCT05447923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo education for colorectal cancer screening
Study NCT05447923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test
Description: Undergo FIT testing
Study NCT05447923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Undergo patient navigation for positive FIT results
Study NCT05447923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire about colorectal cancer screening and healthcare
Study NCT04624230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
Study NCT06310564 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: A biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected \[10\]; if not possible, a BED schedule no lower than 100 Gy10 should be administered. In compliance with these instructions, treatment schedules, total dose and fractionation will be prescribed according to the clinical practice of each participating Center. The constraints for the organs at risk will be respected according to the available data.~In any case, biological effective dose (BED) ≥125 Gy10 should be administered when constraints to the organs at risk (OARs) are respected; if not possible, a BED schedule no lower than 100 Gy10 should be administered.~SABR will be administered before systemic treatment start, or before starting the second systemic treatment cycle at the latest.
Study NCT06294951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: The fMRI is acquired using a Siemens 3.0T MRI scanner. BOLD functional images are scanned using an echo planar imaging (EPI) sequence. The scanning parameters are: TR=2s, matrix size of 64\*64, number of layers=30, layer thickness=3.75\*3.75\*4.5mm, and bottom-up interval scanning. A total of 540 whole brain functional images are acquired.
Study NCT05761067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Description: Alternative treatment
Study NCT06054308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSLN CART
Description: Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells
Study NCT05609253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole in capsule form
Description: Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).
Study NCT05609253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole in solution form
Description: Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).
Study NCT06454188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 MG [Rinvoq]
Description: 15mg tablet once per day.
Study NCT06454188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15mg tablet once per day.
Study NCT05453968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berotralstat
Description: Administered orally once daily at a weight-based dose in up to 4 cohorts
Study NCT05454982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryocompression
Description: A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will circulate ice-water at a constant temperature of 8℃ throughout each test session. Depending on the condition, the cuff will also apply varying levels of pressure for the duration of each test. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature >15℃.
Study NCT06528418 — intervention group
Intervention type: OTHER
Intervention: Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
Description: Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
Study NCT06168006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The experimental group will undergo an exercise program using the Recovery App. Participants will receive guidance from researchers about the functionality of the app. The Recovery App includes flexibility, strength, and aerobic training exercises, aiming for a progressive intensity and volume over the weeks.
Study NCT06168006 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: They will receive an exercise booklet based on the Brazilian Physical Activity Recommendations (MINISTRY OF HEALTH, 2021), which recommend 150 minutes of physical activity for adults and seniors.
Study NCT06562543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Oral capsules
Study NCT05014880 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ICR (Intensive Cardiac Rehabilitation)
Description: Participants in this arm will not have to adopt a 10-hour eating window while taking part in UCSD's 9-week ICR program.
Study NCT05014880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)
Description: Participants in this arm will adhere to a daily, consistent 10-hour eating window while undergoing UCSD's 9-week ICR program to see if there is an improvement on cardiometabolic parameters.
Study NCT05239442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Taste Commission
Description: Evaluation of the daily meal once a week:~Introduction on the different sensory dimensions of the food, hedonic rating for each component, indicate what pleases/what could be improved in the recipe.
Study NCT05239442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the taste commissions
Description: At 0, 3, 6 months:~* Food intake measurement, satisfaction measurement, and food waste measurement performed on 2 days (same week but not necessarily consecutive)~* Assessment of nutritional status using the Mini-Nutritional Assessment (MNA)
Study NCT05239442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Entretien SWOT
Description: Individual semi-guided face-to-face interview with an experimenter. They will allow us to identify the positive and negative effects of the taste commissions in the establishment as well as the levers and difficulties encountered during the implementation of the taste commissions. These interviews will be recorded using an audio device (dictaphone). Their content will then be transcribed in full.
Study NCT04576429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: venous puncture
Description: Venous punctures will be performed:~for patients of cohort A and B1:~* before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~* between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~* each 3 months up to 12 months.~for patients of cohort B2:~* before the radiotherapy;~* within the 6 weeks after the end of radiotherapy;~* at the 2 following evaluations (every 3 months).
Study NCT04576429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venous puncture
Description: Venous punctures will be performed:~for patients of cohort A and B1:~* before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~* between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~* each 3 months up to 12 months.~for patients of cohort B2:~* before the radiotherapy;~* within the 6 weeks after the end of radiotherapy;~* at the 2 following evaluations (every 3 months).
Study NCT04576429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tumoral biopsy
Description: Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
Study NCT04576429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tumoral biopsy
Description: Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
Study NCT05103631 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CATCH T cells
Description: Four different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 3x10\^7/m2~DL2: 1x10\^8/m2~DL3: 3x10\^8/m2~DL4: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells.
Study NCT05485155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-proteinase inhibitor
Description: Intravenous infusion at 120 mg/kg body weight dose/week for 8 weeks for a total of 8 infusions.
Study NCT06276972 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: there's no intervention. it's a cross sectional study correlation study
Study NCT06547645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Acute Rehab at Home
Description: Patients randomized to the intervention group will receive skilled nursing and rehabilitative care at home upon discharge from the hospital, or when eligible for skilled-nursing facility care when requiring a step up in services at home. Home care will be delivered and overseen by a multidisciplinary clinical team, which will develop individualized care plans based on diagnosis, specific rehabilitation objectives, and broader goals of care.
Study NCT04880070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Treatment
Description: Self-controlled, single-arm group using the Shockwave device.
Study NCT05304520 — intervention group
Intervention type: DRUG
Intervention: Natalizumab
Description: Administered as specified in the treatment arm.
Study NCT05057754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooling
Description: Participants' dominant hand and wrist will be immersed in cool water (20°C) for five minutes. The cool water will be kept to around 20°C (19 - 21°C) by frequently checking the temperature and corrected when it rises to 20.5°C
Study NCT05057754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heating
Description: A heat pack wrapped in a towel will be applied to participants' dominant hand for five minutes.
Study NCT05057754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercising
Description: Participants will be asked to participate in moderate-intensity physical activities to induce an increase in blood pressure. The physical activity will be two sets of 30 jumping jacks, followed by 15 squats. Participants are allowed to rest for 20 seconds between the two sets.
Study NCT05057754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Typing
Description: All participants will be asked to perform a typing task with a standard wired keyboard. All subjects will be asked to type for five minutes.
Study NCT05057754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using a mouse
Description: Participants will be asked to draw as many lower-case alphabet characters from a to z as possible using a standardized scroll mouse for five minutes in the Windows Microsoft Paint software.